OligoGpivotalCF and Covid-19: AlgiPharma CF Clinical Trial Operations in Europe

We have now received regulatory approvals from Austria, UK, Germany and Ireland, and ethics approvals from Austria and UK. Ethics approvals from Germany and Ireland are expected to follow soon in order for us to proceed with the OligoGpivotalCF clinical study.

However, due to the current situation with COVID-19, we have decided to postpone site initiation visits until after April 12 (Easter break) to minimize the risk for the CF community.

The Cystic Fibrosis Foundation (CFF) has recently issued guidance, based on recommendations from the US CDC and local health authorities, which we believe is also prudent to adopt here.

See also